[ad_1]
CHICAGO – In a June 2 article on prostate cancer drugs, the Associated Press incorrectly described a study on the drug Erleada. The study tested the drug in men at high risk of spreading cancer beyond the prostate, not among those in whom it had already spread.
A corrected version of the story is below:
Medications progress against lung, breast and prostate cancers
New drugs improve the survival of some people with difficult-to-treat cancers
By MARILYNN MARCHIONE
AP Chief Medical Editor
New drugs dramatically improve the chances of survival for some people with difficult-to-treat lung, breast and prostate cancers, doctors said at the world's largest cancer conference.
Among the recipients is Roszell Mack Jr., who at age 87 is still able to work at an equestrian farm in Lexington, Kentucky, nine years after the diagnosis of lung cancer that occurred in Canada. was spread to the bones and lymph nodes.
"I go there every day, I'm the first one," said Mack, who helped test Merck's Keytruda, a therapy that helps the immune system identify and fight cancer. "I feel good and I have a good quality of life."
The disadvantage: Many of these drugs cost $ 100,000 or more per year, although the cost to patients varies depending on the insurance, income and other criteria.
The findings were presented Saturday and Sunday at the American Society of Clinical Oncology conference in Chicago and some were published by the New England Journal of Medicine. The companies that make the drugs have sponsored the studies and some studies have financial links.
Here are some highlights:
LUNG CANCER
Immunotherapy drugs such as Keytruda have transformed the treatment of many types of cancer, but they are still relatively new and do not help most patients. The longest study to date on Keytruda in patients with advanced lung cancer revealed that 23% of those who had received the drug as part of their initial treatment had survived at least five years, compared to 16 % of those who had tried another treatment.
In the past, only about 5% of these patients lived as long.
"I firmly believe that life time depends not only on the length of life, but on the quality of life," said Dr. Leora Horn of the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee. She enrolled Mack in the study of 550 people.
Mack said that he had manageable side effects – mostly terrible itching – after he started using Keytruda four years ago. He went there last winter and the scanners did not reveal any active cancer; he and his doctor hope it will be in remission.
Last year, a smaller study revealed a five-year survival rate of 16% for similar patients treated with another immunotherapy, Opdivo.
"Both studies give a similar message: when these drugs work, they can have a truly lasting effect," said Horn.
BREAST CANCER
This risk increases with age, but about 48,000 cases in the United States each year involve women under 50 years of age. About 70% of them are "hormonal, HER2-negative" – that is, cancer growth is powered by estrogen or progesterone. and not by the gene that the Herceptin drug targets.
In a study of 672 women with this type of cancer who had spread or who were very advanced, the addition of Novartis Kisqali drug to the usual hormonal inhibitors, because the initial treatment helped more than the hormonal treatment alone.
After 3.5 years, 70% of the women living in Kisqali were alive, compared to 46% of the others. Side effects were more common with Kisqali.
This is the first time that a treatment increases survival beyond what hormone inhibitors do for such patients.
PROSTATE
The options multiply for men with prostate cancer that has spread beyond the gland. The standard treatment consists of drugs that block the male hormone testosterone, which promotes the growth of these cancers, as well as a chemotherapy or a newer drug called Zytiga.
Now another drug has been shown capable of prolonging survival when it was used as chemotherapy or Zytiga in men who were undergoing regular hormonal treatment and who were continuing to cure it.
The study tested Xtandi, sold by Pfizer and Astellas Pharma Inc., in 1,125 men, half of whom also received chemotherapy. After three years, 80% of people who received the standard Xtandi treatment were alive, compared with 72% of men receiving only other treatments.
Men now have the choice between several drugs offering similar benefits, and no study has compared them yet, said Dr. Ethan Basch, prostate specialist at the Lineberger Comprehensive Cancer Center at the University of North Carolina, who has no financial ties with any drug makers.
Costs and side effects can help patients decide, he said. Chemotherapy can cause numbness and tingling in the hands and feet and may not be beneficial for men with diabetes who already have a higher risk of developing this problem. Zytiga must be taken with a steroid; Xtandi can cause falls and fainting.
Chemotherapy has more side effects, but costs much less and only requires four to six intravenous treatments. Other drugs are tablets that cost more than $ 10,000 a month and are taken indefinitely.
"I have patients who refuse to take these drugs because of the cost," Basch said. "Patients have more choices, but it's not clear that more benefits are provided" beyond what chemotherapy gives, he said.
___
Marilynn Marchione can be followed on http://twitter.com/MMarchioneAP
The Health and Science Department of the Associated Press is receiving support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.
[ad_2]
Source link